| Number: 201208091 |
Principal Investigator: Figenshau, R. Sherburne |
| Title: Evaluation of the Off-Clamp Robot-Assisted Partial Nephrectomy Technique in the Management of Renal Tumors |
| Description: A technique where the laparoscopic/robotic kidney surgery is performed without clamping of the blood vessels and without the interruption of the blood flow to the kidney has been developed and is being routinely performed here by your surgeon. It remains unclear whether it is better for kidney func...MORE |
| ___________________________________________________________________________________________________ |
| Number: P2C 9144 |
Principal Investigator: Picus, Joel |
| Title: A Phase II Study of Bevacizumab Alone or In Combination with TRC105 in Advanced Renal Cell Cancer |
| Description: The purpose of this study is to find out whether adding an investigational new drug, TRC105, to a drug called bevacizumab, will result in longer cancer control than bevacizumab alone....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201105396 |
Principal Investigator: Picus, Joel |
| Title: A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients with Metastatic Non-Clear Renal Cell Carcinoma (ASPEN) |
| Description: The purpose of this study is to learn what the effects are of Afinitor or Sutent on patients and kidney cancer. These effects may include the ability of these study drugs to shrink kidney cancer, to keep kidney cancer from growing, to keep kidney cancer from spreading, and to keep kidney cancer fro...MORE |
| ___________________________________________________________________________________________________ |
| Number: CALGB E2810 |
Principal Investigator: Picus, Joel |
| Title: Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastasectomy |
| Description: The purpose of this study is to determine whether taking an oral drug known as pazopanib will reduce the risk of the cancer recurring in the future....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201301006 |
Principal Investigator: Roth, Bruce |
| Title: An International Phase 3, Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT) |
| Description: The purpose of this research study is to see if treatment with AGS-003 (a drug made using a piece of a patient's tumor and a patient's own white blood cells) plus regular medications is any different than treatment with regular medications alone....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201009707 |
Principal Investigator: Grubb, III, Robert |
| Title: A Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects with Localized or Locally Advanced RCC Following Nephrectomy |
| ___________________________________________________________________________________________________ |
| Number: 201103022 |
Principal Investigator: Morrissey, Jeremiah |
| Title: Urine Proteome of Patients Undergoing Surgery |
| ___________________________________________________________________________________________________ |
| Number: 201108327 |
Principal Investigator: Wang-Gillam, Andrea |
| Title: Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies |
| Description: The purpose of this study is to determine the maximum tolerated dose and side effects of the combination of two drugs, temsirolimus and erlotinib, used to treat solid tumor cancers. Temsirolimus is approved by the Food and Drug Administration (FDA) for treatment of renal cancer and is considered inv...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201201112 |
Principal Investigator: Lockhart, A. Craig |
| Title: A Phase 1 First-in-Human Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 172 in Subjects with Relapsed / Refractory Renal Cell Carcinoma |
| Description: The purpose of this research study is to find out more about a study drug called AMG 172 in people with kidney cancer. The study will see if AMG 172 is safe in people who are 18 years of age or older and whether it causes any side effects. This study will also look at what doses of AMG 172 are safe ...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201107068 |
Principal Investigator: Lockhart, A. Craig |
| Title: Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients with Varying Degrees of Hepatic Impairment |
| Description: The purpose of this study is to determine if Cabazitaxel is a safe treatment for patients with advanced cancers of different types who also have different levels of liver dysfunction. The highest safe dose of cabazitaxel (the maximum tolerated dose, or MTD) that can be given to patients with your le...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102468 |
Principal Investigator: Lockhart, A. Craig |
| Title: An Open-Label Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 When Administered as a Single Agent in Patients With
Advanced or Metastatic Solid Tumors |
| Description: There are two parts to this research study. The purpose of Part 1 is to find out the highest safe dose of the investigational drug CEP-9722. “Investigational” means that the study drug has not been approved by the United States Food & Drug Administration (F.D.A). Part 2 of the study is to find out m...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102462 |
Principal Investigator: Lockhart, A. Craig |
| Title: A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects with Advanced Solid Malignancies |
| Description: The main purpose of this study is to find out if the drug ZSTK474 is safe in people who have advanced cancers.
ZSTK474 is an investigational (experimental) drug. This means it has not been approved by the Food and Drug Administration (FDA). It is not currently on the market in any country. This stu...MORE |
| ___________________________________________________________________________________________________ |